Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) Sees Significant Growth in Short Interest

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) was the recipient of a large increase in short interest in February. As of February 13th, there was short interest totaling 2,538,952 shares, an increase of 21.0% from the January 29th total of 2,098,448 shares. Based on an average daily trading volume, of 1,518,433 shares, the short-interest ratio is currently 1.7 days. Approximately 0.3% of the shares of the company are sold short. Approximately 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 1,518,433 shares, the short-interest ratio is currently 1.7 days.

Elite Pharmaceuticals Trading Down 1.7%

Elite Pharmaceuticals stock opened at $0.38 on Wednesday. Elite Pharmaceuticals has a 12-month low of $0.27 and a 12-month high of $0.82. The firm has a market capitalization of $414.11 million, a price-to-earnings ratio of 12.82 and a beta of 0.35. The firm has a 50 day moving average of $0.44 and a 200 day moving average of $0.55. The company has a current ratio of 7.34, a quick ratio of 5.44 and a debt-to-equity ratio of 0.05.

Elite Pharmaceuticals (OTCMKTS:ELTP) last issued its quarterly earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter. The business had revenue of $31.59 million for the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.